Exhibit 10.21
1. LICENSE AGREEMENT OF INTELLECTUAL PROPERTY
THIS LICENSE AGREEMENT OF INTELLECTUAL PROPERTY (the "Agreement") on
the date as appears on the Signature Page of this Agreement is for the License
of Intellectual Property, by and between
THE PARTIES:
VMM, LLC a Limited Liability Company organized and existing under the
laws of the State of North Carolina; and
QT 5, INC., a corporation organized and existing under the laws of the
State of Delaware (hereinafter referred to as the "LICENSEE").
PREMISES:
WHEREAS, LICENSOR has developed and is the proprietary owner of certain
rights, titles and interest in and to technology and information which it owns,
or lawfully possesses for itself or holds valid licenses from others, which it
considers highly proprietary (the "CONFIDENTIAL INFORMATION") regarding certain
technology, and has developed and is the proprietary owner of certain patented
process along with certain rights, titles and interests in and to the technology
and information which it owns, or lawfully possesses. The list of Patents
LICENSOR owns is attached as Exhibit A. the Patent Pending List is attached as
Exhibit B, the FDA 510K Numbers are attached as Exhibit C and the Approved
Platform Products is attached as Exhibit D.
WHEREAS, LICENSOR has obtained from the U.S. Food and Drug
Administration (FDA), under the Trade Name and Devise Name B "DrugStop" FDA No.
K991465 - Regulatory Class II approval for over-the-counter (OTC) sales to the
general public, together with certain other tests trade named "Target System"
This License includes all application of the Target System presently utilized or
which may be developed in the future by either Party to this Agreement.
WHEREAS, LICENSOR'S rights include the right to utilize the patent
process in it's manufacturing of a home drug-screening test. LICENSOR provides,
if necessary, a confirmation service at an additional cost to the customer. The
FDA approved the device that is a preliminary screen to detect and identify the
presence of drugs within the body using a urine sample. The device is designed
to detect the presence of COC (Cocaine, Crack), THC (Marijuana, Pot, Cannabis),
MOR (Opiates, Heroin, Morphine), AMP (Amphetamine, Speed, Metamphetamine), PCP
(Angel Dust).
WHEREAS, LICENSEE is a marketing company that has the capability to
Brand Develop, Manage and provide sales Strategy for all aspects of a full
marketing program to sell and distribute all of LICENSOR'S Intellectual
Properties as set forth in Exhibits A, B, C and D under LICENSEE'S own Brand
Names and under its trademark "Quick Test 5" or any other Brand Names designated
by LICENSEE.
10
WHEREAS, LICENSEE desires to obtain the exclusive rights from LICENSOR
to sell and distribute all Products under its own brand name or names including
all existing Brand names of LICENSOR.
WHEREAS, it is the intent of the LICENSEE to file with the FDA for
clearance to market and sell all the Products under its own Brand Name or Names.
LICENSOR herein agrees to assist, provide documentation, and join in any and all
applications for approval required by the FDA.
NOW, THEREFORE, in consideration of the premises and the mutual
covenants and agreements contained herein, and intending to be legally bound,
LICENSOR and LICENSEE hereby agree as follows:
DEFINITIONS
1.1 Definitions. Whenever used in this Agreement, the Recital above, or
any Exhibit or Schedule hereto, unless otherwise required by the subject matter
or the context, the following terms shall have the meanings respectively
ascribed to them:
(a) "Affiliate," means, in respect to any Person, any other
Person that directly or indirectly, through one or more intermediaries,
controls, is controlled by, or is under common control with such first Person.
(b) "Ancillary Agreements: None at the present time.
(c) "Best knowledge" means, in respect of a Person, that
nothing has come to the attention of that Person that gives such Person actual
knowledge of the existence or absence of any material information or fact
bearing on the matter.
(d) "Claim" means a written notice asserting a breach of a
representation, warranty or covenant specified in the Agreement which shall
reasonably set forth, in light of the information then known to the party giving
such notice, a description of and an estimate (if then reasonable to make) of
the amount involved in such breach or for a claim for injunctive relief.
(e) "Confidential Information" means any confidential or
secret information or data, whether or not reduced to writing, pertaining to the
license product, including scientific or technical knowledge, expertise, skill,
practice, proprietary rights, copyrights, patented or un-patented inventions,
formulas, trade secrets, manufacturing techniques and procedures, analytical
methodology, processes, and data and shall include any and all technology,
pending and existing intellectual property matters, including patenting, and
copyrighting of LICENSOR'S product lines, technologies and inventions, and
future plans and operations done in support of such future plans and operations.
11
Provided however, that in respect of the obligations of either party
hereunder, the term "Confidential Information" shall not include any information
that (i) is now or subsequently enters the public domain through means other
than direct or indirect disclosure by a party in violation of the terms of this
Agreement or (ii) is lawfully communicated to a party by a third party, free of
any confidentiality obligation, subsequent to the date hereof.
"Completion Date" means the date upon which QT 5, Inc. shall
have received written notice to the effect that the FDA has issued to QT 5, Inc.
a Regulatory Clearance in the Field of Activity
"Competing Person" means any Person a substantial majority of
whose business is in the same or similar business of LICENSEE and who is a
direct competitor of LICENSEE or any of its Affiliates that is an Affiliate of
such Person
"Control" means (i) when used in respect of any Person, the
possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of such entity, whether through the
ownership of voting securities, by contract or otherwise, and (ii) when used in
respect of any security, the possession, directly or indirectly, of the power to
vote, or to direct the voting of, such security or the power to dispose of, or
to direct the disposition of, such security.
"Controlling Person" means, in respect of any business
organization or other legal entity, a Person having control of such business,
organization or entity, and any second Person having Control of such first
Person, and so on in an ascending order up to and including the last Person
having Control of the next preceding Person who is not subject to the Control of
any other Person.
"Enhancements" means any change, correction, modification,
improvement, enhancement, addition or revision to the Licensed Products.
"FDA Clearance" means an application to the FDA for the sale
or other distribution of FDA 510k small device for professional use and/or OTC
for the Patent Target System process for the HIV I & II immuno assay HIV Phase
III, as well as all other FDA Clearances obtained by either LICENSOR or LICENSEE
pursuant to this Agreement.
"Governmental Authority" means any governmental body, agency
or official of any county or political subdivision of any country..
"Indemnified Party" means the Person who is entitled to
indemnification for, and to be held harmless in respect of, a claim, cause of
action or any other proceedings, as provided under the terms and subject to the
conditions of this Agreement.
"Indemnifying Party" means the party hereto that is obligated
to indemnify and to hold harmless another Person in respect of a claim, cause of
action or any other proceeding, as provided under the terms and subject to the
conditions of this Agreement.
12
"Intellectual Property" means all intellectual and industrial
property and includes (i) inventions and patents for inventions, including
re-issue thereof and continuation and continuations in part, (ii) computer
programs, (iii) copyrights, (iv) designs and industrial designs, (v) trade
marks, and any word, symbol, icon, logo or other indicia or origin adopted or
used in connection with the license or service and (vi) trade secrets and
confidential information described in (d) above.
"Intellectual Property Rights" means all intellectual and
industrial property and other proprietary rights in respect of Intellectual
Property, and includes all right to Intellectual Property.
"Know-How" means "The Confidential Information" and
proprietary information, including any patents, formula, pattern, compilation,
method, invention, technique or process, used in the creation of the Licensed
Product.
"Person" means a human being, partnership, association, joint
venture, corporation, legal representative, trustee, trustee in bankruptcy,
receiver or any other legal entity whatsoever.
"Licensed Product" means those certain patents and
proprietary rights of LICENSOR as described in Exhibits A, B, C and D.
"LICENSOR" means VMM LLC, a Limited Liability Company
organized and existing under the laws of the State of North Carolina.
"LICENSEE " means QT 5, Inc. a corporation organized and
existing under the laws of the State of Delaware.
"Regulatory Clearance" means (a) (i) in the case of a
product, a clearance by the FDA and (ii) in the case of product clearance by the
FDA for the sale or other disposition of the patent target system for its
specific and intended use; or (b) in the event of any change in the regulatory
process, a clearance similar to the foregoing for the sale and distribution of
said product.
"Third Party Claim" means, in respect of the obligations of
an Indemnifying Party hereunder, a claim asserted against, imposed upon or
incurred by the Indemnified Party by any third party.
"Term" means the term of this Agreement as set forth in
paragraph 2.2 (a) Term.
"Effective Date" means the commencement of the Term of this
Agreement as set forth in paragraph 2.2 (b) below.
"Right of First Refusal" means the right given to LICENSEE of
first refusal as set forth in paragraph 2.2 (c).
13
Additional Terms. The definitions in Section 1.1 shall apply
equally to both the singular and plural forms of the terms defined. Whenever the
context may require, any pronoun shall include the corresponding masculine,
feminine and neuter forms. The words "include," "includes" and "including" and
shall be deemed to be followed by the phrase "without limitation." All
references to "party" and "parties" shall be deemed references to the parties to
this Agreement and to a party's successor in title unless the context shall
otherwise require. All references to Sections and Paragraphs shall be deemed
references to Sections and Paragraphs of this Agreement, unless the context
shall otherwise require. All references herein to Schedules and Exhibits shall
be deemed to be references to the Schedule(s) and Exhibit(s) attached to this
Agreement. The terms "this Agreement", "hereof", "hereunder", and similar
expressions refer to this Agreement as a whole and not to any particular Article
or Section or other portion hereof and include any agreement supplemental
hereto. The conjunction "or" shall be understood in its inclusive sense
(and/or).
Headings . The division of this Agreement into Articles and
Sections and the insertion of headings are for convenience of reference only and
shall not affect the construction or interpretation of this Agreement.
a) ARTICLE 2
2.1 Granting of License.
Subject to the terms and conditions of this Agreement, LICENSOR hereby
grants LICENSEE a right to utilize, sell, or resell all LICENSOR Products as
specified in EXHIBITS A, B, C and D hereof under the LICENSEE'S own Trade Names,
Brand Names and Trademark Worldwide. All products Licensed herein that are
specifically designated for the general public consumption (over the counter)
are warranted by LICENSOR to meet any and all government requirements and
clearances for sale in the over-the-counter market.
2.2 Term
2.2 (a) The Term of this Agreement shall be for one (1) year commencing
as of the Effective Date (defined below). This Agreement shall be extended for
four (4) additional Terms of one (1) each on condition that LICENSEE performs
its sales projections after the Effective Date. The Sales Projections are
attached to this Agreement as Exhibit "E" and incorporated herein by reference.
All of the provisions of this Agreement shall continue in full force and effect
during the extension period and any subsequent extension periods.
This Agreement shall be automatically extended for an additional five (5) years
period so long as neither party causes a termination of this Agreement pursuant
to the terms hereof.
Both Parties recognize that those certain Products that LICENSEE intends to
first market and sell are presently not being manufactured nor has the required
governmental authority cleared them. LICENSOR shall have the duty of providing a
manufacturer for the Products listed in the Exhibits and shall have the duty to
obtain all necessary and required regulatory clearances for the Products.
LICENSEE agrees to collaborate with LICENSOR in obtaining said clearances.
14
2.2 (b) Effective Date: The Term of this Agreement shall become
effective four (4) months after (a) all regulatory clearances required shall
have been obtained for those Products to be manufactured listed in Exhibit A and
shall remain in full force and effect and all statutory waiting periods in
respect of the same shall have expired and no such clearances shall contain any
conditions, restrictions or requirements which LICENSEE reasonably determines
would either before or after the Effective Time have a Material Adverse Effect
on LICESSE in marketing the Products contemplated by this Agreement, taken as a
whole and (b) LICENSOR has obtained a manufacturer to manufacturer said Products
consistent with the Pricing of the Product as set forth in Sales Projections
attached as Exhibit "E".
2.2. (c) Right of First Refusal: LICENSOR herein shall have the right
to sell, assign and transfer its Patent rights to any of the Patents listed in
this Agreement. In the event that LICENSOR receives an offer to purchase said
Patent rights and decides to sell said rights, LICENOR shall first offer the
right to purchase to LICENSEE for the price and the terms of the intended sale.
LICENSEE shall have thirty (30) days from the date that LICENSOR delivers to
LICENSEE a copy of the offer in which to accept or reject. Failure by LICENSEE
to notify LICENSOR shall be construed as a refusal of LICENSEE to exercise its
right of first refusal and LICENSOR shall have the right to sell said Patents.
2.3 Private Label Reseller
LICENSOR acknowledges that it is a PRIVATE LABEL RESELLER (PLR) and
that LICENSEE shall purchase the products under this Agreement for resale in the
over the counter (retail) market together with any and all direct or indirect
markets that LICENSEE shall develop as part of its marketing program. The
LICENSEE shall have the following rights:
(a) The right to utilize as a private label any and all label
approved by the FDA for LICENSOR with LICENSEE'S name, logo or any other label
thereafter selected by LICENSEE and approved by the FDA. In that connection,
LICENSOR shall provide LICENSEE with copies of all documents provided to the FDA
in which it obtained approval for any of the Licensed Products and join with
LICENSEE, if necessary, in any application for said approval for LICENSEE'S
label approval.
(b) Re-market to unaffiliated third party users in the
regular course of business, and/or;
(c) LICENSEE may include LICENSOR product(s) as part of an
integrated set of products sold direct (retail outlets) or through third parties
as a comprehensive product service or consumer solution.
2.4 Use of Trademark
LICENSOR hereby grants LICENSEE the right to use and display LICENSEE'S
trademarks, service marks, and trademarks and trade names that are applicable to
LICENSOR Product(s) under this private labeling agreement. LICENSEE will not use
any of LICENSOR'S Marks as part of its corporate, trade or other business name.
15
(1) ARTICLE 3
3.1 Products
LICENSOR'S Licensed Products are specified in EXHIBITS A, B, C, and D
attached hereof.
(2) ARTICLE 5
REPRESENTATIONS AND WARRANTIES OF THE LICENSOR
To induce the LICENSEE to acquire the License rights, the LICENSOR
hereby makes the following representations and warranties:
5.1 Organization. Standing and Qualifications . The LICENSOR, VMM, LLC
is a Limited Liability company, duly organized, validly existing and in good
standing under the laws of the State of North Carolina. The LICENSOR has full
power and authority to carry on its business as it is now being conducted and to
own the property and assets it now owns. The Individual LICENSORS have full
rights to enter into this Agreement.
5.2 Authorization . The LICENSOR that is a LLC has full power and
authority to execute and deliver this Agreement to consummate the transactions
contemplated hereby. The execution, delivery and performance of this Agreement
and the consummation of the transactions contemplated hereby have been duly
authorized by all necessary action required by law, the LICENSOR'S Articles or
otherwise to be taken by the LICENSOR to authorize the execution and delivery of
this Agreement and the agreements specified herein or the consummation of the
transactions contemplated hereby and thereby.
5.3 Binding Agreements. This Agreement constitutes the legal, valid and
binding obligations of the LICENSOR, enforceable in accordance with its terms.
5.4 No Violation. Neither the execution and delivery by the LICENSOR of
this Agreement nor the consummation by the LICENSOR of the transactions
contemplated hereby will (a) violate any provision of the Articles of VMM, LLC;
(b) conflict with or violate any statute, law, regulation, rule, order, judgment
or decree of any court or Governmental Authority binding upon or applicable to
the LICENSOR. The LICENSOR is not a party to, nor is it bound by, and the
LICENSOR Product Line are not subject to, any agreement or commitment that
prohibits the execution and delivery by the LICENSEE of this Agreement or the
consummation of the transactions contemplated hereby.
5.5 Litigation. No action, suit, inquiry, audit, or to the Best
Knowledge of the LICENSOR no proceeding or investigation, by or before any court
or governmental or other regulatory or administrative agency or commission is
currently pending or, to the Best Knowledge of the LICENSOR threatened, against,
involving or arising in connection with the LICENSOR'S Product Line or that
questions or challenges the validity of this Agreement or any action taken or to
be taken by the LICENSOR pursuant to this Agreement.
16
5.6 Right to License LICENSOR'S Product Line. LICENSOR has the right to
license the intellectual property as described in Exhibits A, B, C, and D and
the right to manufacture Products utilizing said intellectual property rights
and patents.
5.7 Intellectual Property Rights.
To the Best Knowledge of the LICENSOR, the License rights and
the use thereof will not infringe upon or violate any Patent and Intellectual
Property Right of any Third Person. Further, LICENSOR herein agrees that it
shall renew any and all patents required to insure the rights of both LICENSOR
and LICENSEE under this Agreement.
2. ARTICLE 6
REPRESENTATIONS AND WARRANTIES OF THE LICENSEE
To induce the LICENSOR to enter into this License Agreement with the LICENSEE,
the LICENSEE hereby represents and warrants to the LICENSOR as follows:
6.1 Corporate Organization and Good Standing. The LICENSEE is a
Company, duly organized, validly existing and in good standing under the laws of
the State of Delaware.
6.2 Authorization. The LICENSEE has full corporate power and authority
to execute and deliver this Agreement and to consummate the transactions
contemplated hereby. The execution, delivery and performance of this Agreement
and the consummation of the transactions contemplated hereby and thereby have
been duly authorized by all necessary corporate action required by law, the
LICENSEE'S Articles of Incorporation, or otherwise to be taken by the LICENSEE
to authorize the execution and delivery of this Agreement and the consummation
of the transactions contemplated hereby.
6.3 Binding Agreements. This Agreement constitutes the legal, valid and
binding agreements of the LICENSEE enforceable in accordance with its terms.
6.4 No Violation. Neither the execution and delivery by the LICENSEE of
this Agreement nor the consummation by the LICENSEE of the transactions
contemplated hereby, will (a) violate any provisions of the Articles of
Incorporation of the LICENSEE; (b) conflict with or violate any statute, law,
regulation, rule, order, judgment or decree of any court or Governmental
Authority binding upon or applicable to the LICENSEE or by which the property or
assets of the LICENSEE are bound or affected.
6.5 Litigation. No action, suit, inquiry, audit, or to the Best
Knowledge of the LICENSEE no proceeding or investigation, by or before any court
or governmental or other regulatory or administrative agency or commission is
currently pending or, to the Best Knowledge of the LICENSEE threatened, against,
involving or arising in connection with the LICENSEE entering into this
Agreement or that questions or challenges the validity of this Agreement or any
action taken or to be taken by the LICENSEE pursuant to this Agreement.
17
ARTICLE 7
COVENANTS OF THE PARTIES
7.1 Cooperation.
(a) Each party shall cooperate reasonably with the other in
preparing and filing all notices, applications, reports and other instruments
and documents which are required by any statute, rule, regulation or order of
any Governmental Authority in connection with the transactions contemplated by
this Agreement, including the Private Label of the licensed Product with the
FDA.
(b) LICENSEE agrees not to use or exploit LICENSOR'S Product
Line in a manner that can be reasonably foreseen to bring it into disrepute or
materially diminish the value of exploiting such Product Line in connection with
the marketing, promotion, distribution, sale, licensing or use of the Products.
ARTICLE 8
3. CONFIDENTIAL INFORMATION
8.1 Confidentiality of Intellectual Property of LICENSOR and Customer
Proprietary Marketing Data of LICENSEE
It is expressly understood and agreed that all intellectual property
and data furnished to LICENSEE by LICENSOR or any information or data regarding
customers or data provided by LICENSEE to LICENSOR and such data as may be
provided by one to the other regarding and including that required for the
proper marketing, sale or re-sale of its products, all of which constitutes a
valuable intellectual proprietary property and trade secret(s) of LICENSOR or
LICENSEE, as the respective party providing such data has divulged. Providing
such material, under any circumstances, shall not constitute a grant of any
right of reproduction, manufacturing, distributing, resale, re-licensing (except
as later set forth) or ownership in any manner whatsoever. Both LICENSEE and
LICENSOR agree that:
(a) To observe complete confidentiality with regard to all aspects of
such data including, without limitation, agreeing not to disclose or otherwise
permit any other person or entity access to, in any manner, any such data in any
form whatsoever. Such disclosure or access shall only be permitted to an
employee of LICENSOR or LICENSEE as the case might be of the Marketing Plans,
Business Relationships, Automated Customer Service (CRM) Systems and any other
proprietary business or client information as permitted and on the terms and
conditions defined in this License Agreement;
18
(b) To ensure that both LICENSOR and LICENSEE and their respective
employees, agents, representatives, independent contractors, customers, sub
contractors or sub LICENSEE'S and business invitee's and guests are advised of
the confidential nature of such data and to insure by agreement or otherwise
that they are prohibited from copying or revealing, for any purpose whatsoever,
the contents of the data;
(c) LICENSEE shall not alter or remove any copyright or proprietary
rights notice of identification, which indicates LICENSOR'S ownership of the
Product. LICENSOR shall not alter or remove any proprietary rights, notice of
identification, which indicates LICENSEE'S confidential data, including customer
data:
(d) Each respective party agrees to notify the other promptly and in
writing of the circumstances surrounding any possession, use or knowledge of any
such data of which either LICENSOR or LICENSEE has knowledge by any person or
entity other than those authorized;
(e) Each respective party agrees to take any and all actions reasonably
necessary or desirable to ensure continued confidentiality and protection of all
such data and to prevent access to such data by any person or entity not
authorized by this section.
Should this Agreement terminate for any reason (including without
limitation, breach by LICENSEE of any of its obligations hereunder), the
confidentiality provisions of this Agreement shall survive the termination of
this Agreement and shall continue to be binding upon both LICENSOR and LICENSEE.
(a) ARTICLE 9
PROTECTION OF THE LICENSOR'S RIGHTS
9.1 Notice of Infringement or Unauthorized Use. LICENSEE shall promptly
inform LICENSOR in writing of any act of infringement, unauthorized use, piracy
or misappropriation of, or breach of any confidentiality agreement pertaining
to, or in any way affecting, the Licensed Property, or any Enhancements thereto,
that are discovered by LICENSEE or are otherwise brought to its attention. Each
party shall promptly inform the other party in writing of any notice of claim or
action, or any threatened claim or action, against either party by any third
Person arising out of in any way related to the Licensed Product.
9.2 Institution. Prosecution and Defense of Claims.
(a) (i) Promptly following the delivery to the LICENSOR of
notice from the LICENSEE of any act of any infringement, unauthorized use,
piracy or misappropriation of, or breach of any confidentiality agreement or
affecting the Licensed Property, or, in the case where such infringement,
unauthorized use, piracy misappropriation or breach is discovered by the
LICENSEE or is otherwise brought to its attention and the LICENSEE provides to
the LICENSOR written notice thereof, then promptly following the delivery of
such notice to the LICENSOR, the LICENSOR shall take such steps as shall be
necessary in order to protect the LICENSEE and the LICENSOR'S rights with
respect to the said Licensed Property, respectively, including, but not limited
to, instituting or authorizing others to institute any claim, suit or proceeding
at law or in equity arising out of or related to the infringement, unauthorized
use, piracy or misappropriation of, or breach of any confidentiality agreement
pertaining to, or in any way affecting the Licensed Property.
19
(ii) The institution, prosecution, maintenance and control of
any claim, suit or proceeding at law or in equity arising out of or related to,
or in any way affecting the Licensed Property shall be subject to the direction
and control of the LICENSOR, at its sole cost and expense, and any and all sums
that may be received, obtained, collected or recovered in any such claim, suit
or proceeding, whether by decree, judgment, settlement or otherwise, shall be
the sole and exclusive property of the LICENSOR.
(b) If requested by LICENSOR, LICENSEE shall join the LICENSOR as, a
party complainant in any such claim, suit or proceeding.
(c) LICENSOR shall defend, at its own expense, any claim that a
Third-Party shall institute effecting the Licensed Product granted to the
LICENSEE herein. LICENSEE shall cooperate fully in the defense of any such
claim, suit or proceeding against any party by a third Person, brought in
connection with, arising out of or related to the Licensed Property, and each
party shall execute such documents and take such actions as may be reasonably
requested by the other party and consistent with the rights and obligations of
the parties hereunder.
(d) LICENSOR shall indemnify LICENSEE for any costs, damages, or other
expenses suffered by LICENSEE in connection with any Third-Party claiming that
said Third-Party is the owner or has rights to the Licensed Product licensed to
LICENSEE.
(e) LICENSEE, in its sole discretion, and with the consent of LICENSOR,
undertake to institute and prosecute any claim, suit or proceeding at law or in
equity arising out of or related to, or in any way affecting the Licensed
Property in which case it shall be subject to the direction and control of the
LICENSEE, at its sole cost and expense, and any and all sums that may be
received, obtained, collected or recovered in any such claim, suit or
proceeding, whether by decree, judgment, settlement or otherwise, shall be the
sole and exclusive property of the LICENSEE. If requested by LICENSEE, LICENSOR
shall join the LICENSEE as, a party complainant in any such claim, suit or
proceeding
4. ARTICLE 10
INDEMNIFICATION
10.1 Survival of Representations and Warranties and Covenants. Except
as otherwise expressly provided herein, all representations and warranties made
by any party in this Agreement shall survive from and after the date hereof and
shall continue in effect for a period of two (2) years from the date hereof, and
all covenants made by any party in this Agreement shall survive indefinitely
unless otherwise terminated by the parties. Any right of indemnification
pursuant to this Article 13 in respect of a claimed breach of any
representation, warranty or covenant shall expire at the date of expiration of
the representation, warranty or covenant claimed to be breached (the "Expiration
Date"), unless on or prior to the Expiration Date a Claim has been made against
the party from whom indemnification is sought. If a Claim is timely made, it may
continue to be asserted beyond the Expiration Date of the representation,
warranty or covenant to which such Claim relates.
20
10.2 Indemnification.
(a) The LICENSOR hereby agrees to indemnify and hold harmless
LICENSEE from and against all Damages asserted against, imposed upon or incurred
by LICENSEE, directly or indirectly, by reason of or resulting from, any breach
or inaccuracy of any representation, warranty or covenant of the LICENSOR set
forth in this Agreement.
(b) The LICENSEE hereby agrees to indemnify and hold harmless
LICENSOR from and against all Damages asserted against, imposed upon or incurred
by LICENSOR, directly or indirectly, by reason of or resulting from any breach
or inaccuracy of any representation, warranty or covenant of the LICENSEE set
forth in this Agreement.
10.3 Limitation of Indemnification. LICENSOR herein shall be obligated
to indemnify LICENSEE for only such Third-Party Claims that are established by a
court judgment or order against LICENSEE involving and limited to the
Proprietary Patent(s) or any Enhancements thereto. The obligations and
liabilities of LICENSOR to indemnify LICENSEE shall be subject to the following
terms and conditions:
(a) LICENSOR shall indemnify and save LICENSEE harmless from
all liability for actual infringement of any Third-Party Patent(s) claimed by
said Third-Party to be the Patent(s) used and developed by LICENSOR. And,
LICENSOR shall indemnify and save LICENSEE harmless from and against all costs,
counsel fees, expenses and liabilities incurred in or about any claim of or
action for such infringement; provided however, that LICENSEE shall promptly
notify LICENSOR, in writing of said Third-Party Claim and transmit to LICENSOR
all papers served on LICENSEE in any suit involving such claim of infringement,
and provided further, that LICENSEE permits LICENSOR to have entire charge and
control of the defense of any such suit.
(b) LICENSEE shall provide LICENSOR with all records and
documents within the LICENSEE'S possession, custody, or control relating to any
Third-Party Claim. Nothing in this provision shall be deemed to constitute a
waiver of any attorney-client, work-product or joint defense privilege.
(c) LICENSOR'S indemnity obligation set forth in this Section
shall survive the termination or expiration of this Agreement with respect to
the Third-Party's Claim of rights to the Proprietary Patent(s) of LICENSOR which
occurs during the Term.
21
ARTICLE 11
5.
6. TERMINATION
11.1 Termination of this Agreement
If either party breaches a material provision of this Agreement and
fails to cure such violation within thirty (30) days after written notice of
said breach has been mailed by the other party, this Agreement shall terminate.
Upon termination, the terms and conditions herein will continue to apply to
LICENSOR Products owned by LICENSEE. If any outstanding debts are owing to
either party by the other, these amounts shall become due and payable
immediately.
A. LICENSEE'S Default. If any of the following events occur, LICENSEE
shall be in default and LICENSOR shall have the right to immediately terminate
this Agreement upon written notice to LICENSEE.
If LICENSEE ceases to function as a going concern, or becomes
insolvent, makes an assignment for the benefit of creditors, files a petition in
bankruptcy, permits a petition in bankruptcy to be filed against it, or admits
in writing its inability to pay its debts as they mature or if a receiver is
appointed for a substantial part of its assets;
LICENSEE ceases to carry on the business of a LICENSEE of LICENSOR'S
Products;
B. LICENSOR'S Default. If any of the following events occur, LICENSOR
shall be in default and LICENSEE, at its option, shall have the right to
terminate this Agreement upon thirty (30) days written notice to LICENSOR.
LICENSOR ceases to function as a going concern, or becomes insolvent,
makes an assignment for the benefit of creditors, files a petition in
bankruptcy, permits a petition in bankruptcy to be filed against it, or admits
in writing its inability to pay its debts as they mature or if a receiver is
appointed for a substantial part of its assets;
C. Obligations on Termination. Upon termination of this Agreement for
any reason whatsoever, LICENSEE and LICENSOR shall perform each and all of the
following obligations, all of which shall survive such termination:
(ii) LICENSEE shall discontinue the use of any LICENSOR trade
or service Marks.
(ii) LICENSEE will promptly refer to LICENSOR the details of
any verbal or written inquiries LICENSEE may receive regarding any of LICENSOR'S
Products, and, in the case of written inquiries, will provide copies thereof to
LICENSOR;
(iii) LICENSEE shall do all other things as LICENSOR may
reasonably request for the purpose of terminating LICENSEE'S business and
contractual arrangements with LICENSOR and effecting an orderly transition of
sales and/or service from LICENSEE to LICENSOR.
22
ARTICLE 12
(i) CONSIDETRATION
12.1 Consideration for exclusive License.
Upon the execution of this Agreement LICENSEE herein shall
issue to LICENSOR and/or nominees Two Million Two Hundred Sixty Thousand Six
Hundred (2,260,600) Shares of LICENSEE'S (QT 5, Inc.) common stock (144
restricted) in addition to One Million One Hundred Sixty (1,000,160) shares have
been previously issued to Xxxxxx Xxxxxx that he is holding in escrow and that
shall be released to him upon the execution of this Agreement.
Therefore, the total stock consideration is Three Million Two Hundred Sixty
Thousand Seven Hundred Sixty Shares. Said shares of stock represent the
consideration paid by LICENSEE to LICENSOR for the exclusive rights granted
under this Agreement
Removal of Legend LICENSEE shall remove any legend on the Shares within 10
days of the certificate qualifying for the removal of such legends due to
registration compliance with Rule 144 or otherwise.
ARTICLE 13
MISCELLANEOUS PROVISIONS
13.1 Notices
(a) All notices, request, demands and other communications
which are required or may be given pursuant to the terms of this Agreement shall
be in writing and shall be deemed delivered (i) on the date of delivery when
delivered by hand; (ii) on the date of transmission when sent by facsimile
transmission during normal business hours with telephone confirmation of
receipt; (iii) on the next business day after transmission when sent by
facsimile transmission after normal business hours; (iv) two (2) days after
dispatch when sent by a reputable courier service that maintains records of
receipt or (v) five (5) days after dispatch when sent by registered mail,
postage prepaid, return=receipt requested; provided that, in any such case, such
communication is addressed provided in the immediately following paragraph (b).
(b) All notices, request, demands and other communications,
which are required or may be given pursuant to the terms of this Agreement shall
be addressed as follows:
(i) If to LICENSOR.
0000 Xxxx Xxxxxx
Xxxx xx Xxxxxxxx
Xxxxxxxxxx 00000.
Telephone: (000) 000 0000
Facsimile: (000) 000 0000
23
(ii) If to LICENSEE.
QT 5, INC.
Xxxxxxx Xxxxxx Xxxx
Xxxxx 000
Xxxxxxxx Xxxxxxx, XX 00000
Telephone: 000 000 0000
Facsimile: 000 000 0000
Or to such other address as any party shall have designated by notice in the
foregoing manner to the other parties.
13.2 Compliance with Laws. In connection with the License granted
herein and the consummation of the transactions contemplated hereby and the
performance by a party of its obligations hereunder, each of the LICENSOR and
the LICENSEE shall comply with all applicable laws, requirements, rules,
regulations and standards of Governmental Authorities of any pertinent
jurisdiction so that neither of the parties shall be subject to any fines or
penalties; or violate any laws or regulations affecting the lease, license and
sale of the Products contemplated herein.
13.3 Authority to Contract and Perform. Both LICENSOR and LICENSEE
represents that they each respectively have full right and authority to enter
into this Agreement and to perform its obligations and that it has not made and
will not make any contract or commitment contrary to the terms of this
Agreement.
134 Ethics and Compliance with Law. Both LICENSOR and LICENSEE covenant
each with the other, that they will maintain the highest ethical business
standards and avoid and refrain from being involved in any activities which may
in any manner disparage the LICENSOR'S or LICENSEE'S Products. Furthermore in
the conduct of its business, both LICENSOR and LICENSEE will comply with all
applicable Federal, State and local laws, rules and regulations.
13.5 Choice of Law. The validity, construction and performance of the
Agreement shall be interpreted, construed and enforces according to the laws of
the State of California.
13.6 Arbitration. Except for any controversy or claim arising after
either party has become insolvent, bankrupt, enters into a composition with
creditors, or has a receiver appointed for any of its properties, any
controversy or claim arising out of or relating to this Agreement will be
settled by arbitration or mediation in Los Angeles County, California in
accordance with the rules, then in effect, of the Judicial Arbitration and
Mediation Service, its successor or a similar alternative dispute resolution
entity. Judgment upon award rendered may be entered in any court of competent
jurisdiction. Whichever party prevails will be entitled to recover all of its
expenses, cost, and reasonable attorney fees as they relate to the arbitration
proceedings, to any litigation or proceeding arising out of or relating to this
Agreement to compel arbitration, or to enforce an award. The Parties shall have
the rights of discovery as provided in the California Code of Civil Procedure
the same as if said action was filed in a judicial proceeding.
24
13.7 Entire Agreement. This Agreement (together with the Schedules and
the Exhibits expressly identified in this Agreement) constitutes the entire
agreement of the parties with respect to the subject matter hereof and thereof,
and supersedes all prior agreements and understandings of the parties, oral and
written, in respect of such subject matter.
13.8 Binding Effect. This Agreement binds and insures the benefit of
the parties hereto, their respective heirs, representatives, successors or
assigns.
(b) 13.9 Paragraph Headings. The paragraph headings in this
Agreement are for convenience only, and they have no substantive or interpretive
effect.
13.10 Waiver. Neither modification of this Agreement nor any waiver of
any term or condition hereof shall be effective unless it is in writing and
signed by the parties hereto. If either party fails to meet the requirements of
any term of this Agreement or waives any breach hereunder, that failure or
waiver will neither prevent a subsequent enforcement of such term nor be deemed
a waiver of any subsequent breach.
13.11 Partial Invalidity. In the event of the determination that any
terms, covenant or condition of this Agreement is of no force or effect, the
remaining terms, conditions or covenants contained herein shall not be affected
thereby, and the obligations of the parties hereto with respect to the
performance of the remaining terms, covenants and conditions shall continue in
full force and effect.
13.12 Assignment. Either Party may assign this Agreement.
13.13 Indemnity. LICENSOR and LICENSEE agree to each hold the other
free and harmless from any and all claims, damages and expenses of any kind or
nature whatsoever: (1) arising from acts of the other; or (2) as a direct or
indirect consequence of termination of this Agreement in accordance with its
terms. LICENSOR agrees to hold LICENSEE free and harmless from any and all
claims, damages, and expenses of any kind or nature including attorneys fees and
costs arising out of any claim of patent or other infringements by a third party
as it relates to the use by LICENSEE of product(s) supplied to LICENSEE by
LICENSOR. Further, LICENSEE is relying on the representations of LICENSOR that
it has the approval from the FDA for over-the-counter sales to the general
public. In that regard, LICENSOR agrees to hold LICENSEE free and harmless from
any and all claims, damages, and expenses of any kind or nature including
attorney fees and cost arising out of any claim from the FDA or any other
governmental agency regarding the sale of the product to the public. This
indemnification shall be void and of no force or effect if LICENSEE fails to
obey or comply with any reasonable instruction or limitation imposed by LICENSOR
or the FDA. This section shall inure to the benefit of anyone who buys
product(s) from LICENSEE that was supplied by LICENSOR.
25
(c) 13.14 Execution in Counterparts. This Agreement may be
executed in two or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument.
13.15 Relationship of the Parties. LICENSEE is an independent
contractor and private labeler. Nothing in this Agreement will be deemed or
construed to create an agency, partnership, joint venture or employment
relationship between LICENSOR and LICENSEE. LICENSEE will, under no
circumstances, represent itself directly or by implication, as LICENSOR'S agent
or employee, nor will LICENSEE purport or attempt to bind LICENSOR to any
liability or obligation whatsoever. Nothing contained herein will impose any
liability on LICENSOR in connection with the operation of LICENSEE'S business,
or for any expenditure, obligation or liability incurred by LICENSEE in
performing or preparing to perform, any of its obligations under this Agreement.
The credit risk with respect to sales by LICENSEE to its customers will be borne
by LICENSEE, and the collectibles of any amount due LICENSEE will in no respect
eliminate, reduce or otherwise affect an obligation of LICENSEE to LICENSOR.
13.16 Amendment. This Agreement may only be modified, supplemented or
amended by a written instrument executed by the parties to it.
13.17 Conditions Precedent. Each and every provision of this Agreement
shall be contingent and become effective only upon the execution and delivery of
the Intellectual Property hereinabove described.
13.18 Schedules. Exhibits and Other Agreements.
(a) The Schedules, Exhibits and other agreements specifically
referred to in, and delivered pursuant to, this Agreement are an integral part
of it. Any disclosure that is made in any of the Schedules delivered pursuant to
this Agreement shall be deemed responsive to any other applicable disclosure
obligation hereunder.
(b) The following are the Exhibits and Schedules annexed
hereto and incorporated by reference and deemed to be part hereof:
(i) Exhibits:
Exhibit A - List of Patents of Licensor
Exhibit B - Patent Pending List
Exhibit C - FDA 510K Numbers
Exhibit D - Approved Platform Products
Exhibit E - Sales Projections
13.19 [Intentionally Omitted]
7.
8. SIGNATURE PAGE
26
IN WITNESS WHEREOF, LICENSOR and LICENSEE have executed this Agreement
the day and year written below.
LICENSOR LICENSEE
VMM, LLC QT 5. INC.
0000 Xxxxxxx Xxxxxx Xx. # 000
___________________ Xxxxxxxx Xxxxxxx, Xxxxxxxxxx, 00000
Dated: _____________, 2003 Dated: ___________________, 2003
BY: _______________________________ BY:________________________________
Managing Member Xxxxxxx X. Xxxxx
Its: CEO
(i) XXXXXX XXXXXX
--------------------------------------------------------------------------------
Dated: ______________________, 2003
BY: ______________________
Xxxxxx Xxxxxx
EXHIBIT A
Target System and Drug Test Cup. Patent numbers
9. Patents Issued Target System
0.Xx 4,748,042 5/31/88 Target Ringing & Spotting Machine (method and Apparatus for
imprinting membrane with pattern of antibody)
0.Xx 4,797,260 1/10/89 Target Cassette (Antibody testing system)
0.Xx 5,036,569 8/6/61 Target Filter/Funnel Assembly Machine (Apparatus for automatically
assembling filter into funnel).
0.Xx 5,137,691 8/11/92 Target Cassette with Removable Air Gap (Antibody testing system with
removable air gap)
0.Xx 5,334,538 8/2/94 Gold Sol Immunoassay System and Device (A system for one step
immunoassay testing).
27
10. EXHIBIT B
11.
12. Patent Pending
Application Number 09752712 Drug Test Cup
28
EXHIBIT C
FDA 510K NUMBERS
K892231 V-Trend Target CPR April 21, 1989
K885254 Target Reader January 27, 1989
K980153 Drug Cup (Professional) March 27, 1998
K991465 Drug Cup (OTC) December 10, 1999
K890295/B Target CK-MB August 15, 1989
K972094 Target Cardiac Troponin I July 23, 1997
L963680/51 Target Myoglobin February 6, 1997
29
13. EXHIBIT D
APPROVED PLATFORM PRODUCTS
HCG- Human chorionic gonadotropin (Pregnancy Test) Rapid enzyme immunoassay test
for qualitative detection of HCG in urine, serum and plasma. HCG is a hormone
produced by the developing placenta. Serum and urine levels of HCG climb
rapidly, starting as soon as the week following implantation, reaching peak
levels near the end of the first trimester. One-step technology offers superior
speed and simplicity without sacrificing sensitive and specific results.
Strep A Detects group A streptococci, the cause of upper respiratory infections
and pharyngitis. Identification is essential for the selection of appropriate
antibiotic therapy to avoid complications such as acute glomerulonephritis or
rheumatic fever. The test detects group A strep antigen directly from extracted
throat swabs or swabs from culture plates for test confirmation.
CK-MB Creatine Kinase (CK) Muscle (M) Brain (B) Rapid immunoassay for the
quantitative detection of CK-MB. CK-MB measurements in serum can provide useful
information to help confirm or exclude that myocardial infraction has occurred.
The amount of CK-MB released can also assess the infract size. CK_MB is found
predominantly in the myocardial tissue. Detectable increases in CK-MB levels
from non-cardiac sources are rare.
Myoglobin Rapid enzyme immunoassay test for the quantitative detecti9on of
Myoglobin in serum and plasmas an aid in the rapid diagnosis of acute myocardial
infarction.
Troponin I Rapid enzyme immunoassay test for the quantitative determination of
cardiac troponin I in serum and plasma as an aid in the rapid diagnosis of
myocardial in fraction. Troponin is a thin filament associated complex of the
myocyte. Troponin I is a protein with a high specificity for cardiac injury.
Rubella Rapid enzyme immunoassay test for qualitative detection of rubella virus
specific IgG antibody. Rubella is a highly contagious yet generally mild disease
in most people. However, it has great significance in women infected with
rubella, the virus may infect the placenta, multiply and induce serious damage
to the fetus, including low birth weight, cardio vascular detects, mental
retardation and bone defects. Therefore, all women of child bearing age, as
well, as school age children and healthcare personnel should be screened for
immunity to rubella.
CMV Rapid enzyme immunoassay for qualitative detection of antibody to
Cytomegalovirus in serum and plasma. Cytomegalovirus (CMV) is human viral
pathogen belonging to the herpes family. Infection in humans is wide spread and
usually results in asymptomatic disease. However, severe symptomatic infections
a very significant risk in infants and immunocomprised patients.
30
Rotavirus Rapid enzyme immunoassay test for qualitative detection of human
rotavirus particles and antigens in human fecal specimens. Rotavirus is a major
cause of gastroenteritis in infants, young children and the elderly. During the
winter months a portion of gastroenterics in children is due to rotavirus
infection. The disease manifests with the symptoms of vomiting diarrhea, and
fever. Rapid and accurate diagnosis is important to avoid inappropriate
antibiotic therapy, provide proper treatment early and to prevent spread of
nosocmial infection.
Mono Qualitative and quantitative detection of heterophile antibodies associated
with infectious mononucleosis. IM is an acute disease caused by the Xxxxxxx Xxxx
virus. Heterophile antibodies are the primary antibodies, which appear in the
patient's serum, usually 1 to3 weeks after the onset of symptoms Common symptoms
include fatigue, pharyngitis, fever, lymphadenopatherapy and splenomegaly.
CRP C-reactive protein is an acute phase protection. The test is a solid phase
gold immunoassay for the detection of CRP. Quantitative CRP measurements have
been found to provide reliable early indication of postoperative inflammatory
complications if monitored on a daily basis. CRP is also predictive of clinical
cardiovascular disease.
READER The Reader is designed to interpret selected membrane enzyme
immunoassays. The instrument is designed for laboratory, emergency room or field
use and requires only a few minutes to learn to operate. The reader permits more
precise, accurate readings of test results than visual interpretation.
(A)
31
14. EXHIBIT E
SALES PROJECTIONS
Please see following two-page projection.
EXHIBIT E PAGE 1 OF 2
SALES PROJECTIONS
Year 1 >>
Month >>> 1 2 3 4 5 6
-----------------------------------------------------------------------------------
--------------
DEVICES
--------------
Qualitative
-----------------------------------
HIV 1 and 2
Total No. of Units
Bulk 80% No. of Units - - - - - -
Cost per Unit * $ 6.50 $ 6.50 $ 6.50 $ 6.50 $ 6.50 $ 6.50
Individually Package20% No. of Units - - - - - -
Cost per Unit * $ 7.50 $ 7.50 $ 7.50 $ 7.50 $ 7.50 $ 7.50
Six Additional Devices No of Units - - - - - -
Rubella Cost per Unit * $ 7.50 $ 7.50 $ 7.50 $ 7.50 $ 7.50 $ 7.50
CMV (Herpes)
Rotavirus
Streptococci Group A
HCG (Pregnancy)
Infectious Mononucleosis (Heterophile)
Quantitative
-----------------------------------
Cardiac System
Myoglobin No. of Units - - - - - -
CK - MB No. of Units - - - - - -
Cardiac Troponin - 1 No. of Units - - - - - -
Cost per Unit * $ 5.00 $ 5.00 $ 5.00 $ 5.00 $ 5.00 $ 5.00
Initial CRP Device and two No. of Units - - - - - -
additional new tests per quarteCost per Unit * $ 8.50 $ 8.50 $ 8.50 $ 8.50 $ 8.50 $ 8.50
Multiple Mobile Assay Analyzer
-----------------------------------------
No. of Units - - - - - -
Cost per Unit * $ 300 $ 300 $ 300 $ 300 $ 300 $ 300
-----------------------------------
DRUG TESTS
-----------------------------------
Drug Cup
Total No. of Units - - - 20,000 40,000 60,000
Bulk 80% No. of Units - - - 16,000 32,000 48,000
Cost per Unit * $ 5.00 $ 5.00 $ 5.00 $ 5.00 $ 5.00 $ 5.00
Individually Packa20% No. of Units - - - 4,000 8,000 12,000
Cost per Unit * $ 6.00 $ 6.00 $ 6.00 $ 6.00 $ 6.00 $ 6.00
Total
Month >>> 7 8 9 10 11 12 Year 1
---------------------------------------------------------------------------------------------
--------------
DEVICES
--------------
Qualitative
--------------------------
HIV 1 and 2
Total No. of Units 10,000 17,500 25,000 35,000 45,000 55,000 187,500
Bulk 80% No. of Units 8,000 14,000 20,000 28,000 36,000 44,000 150,000
Cost per Unit * $ 6.50 $ 6.50 $ 6.50 $ 6.50 $ 6.50 $ 6.50
Individually Package20% No. of Units 2,000 3,500 5,000 7,000 9,000 11,000 37,500
Cost per Unit * $ 7.50 $ 7.50 $ 7.50 $ 7.50 $ 7.50 $ 7.50
Six Additional Devices No of Units 2,000 3,500 5,000 7,000 9,000 11,000 37,500
Rubella Cost per Unit * $ 7.50 $ 7.50 $ 7.50 $ 7.50 $ 7.50 $ 7.50
CMV (Herpes)
Rotavirus
Streptococci Group A
HCG (Pregnancy)
Infectious Mononucleosis (Heterophile)
Quantitative
--------------------------
Cardiac System
Myoglobin No. of Units 10,000 17,500 25,000 35,000 45,000 55,000 187,500
CK - MB No. of Units 20,000 35,000 50,000 70,000 90,000 110,000 375,000
Cardiac Troponin - 1 No. of Units 20,000 35,000 50,000 70,000 90,000 110,000 375,000
Cost per Unit * $ 5.00 $ 5.00 $ 5.00 $ 5.00 $ 5.00 $ 5.00
Initial CRP Device and two No. of Units 10,000 17,500 25,000 35,000 45,000 55,000 187,500
additional new tests per quarteCost per Unit * $ 8.50 $ 8.50 $ 8.50 $ 8.50 $ 8.50 $ 8.50
Multiple Mobile Assay Analyzer
------------------------------
No. of Units 300 525 750 1,050 1,350 1,650 5,625
Cost per Unit * $ 300 $ 300 $ 300 $ 300 $ 300 $ 300
-----------------------------------
DRUG TESTS
-----------------------------------
Drug Cup
Total No. of Units 80,000 100,000 120,000 150,000 180,000 210,000 960,000
Bulk 80% No. of Units 64,000 80,000 96,000 120,000 144,000 168,000 768,000
Cost per Unit * $ 5.00 $ 5.00 $ 5.00 $ 5.00 $ 5.00 $ 5.00
Individually Packa 20% No. of Units 16,000 20,000 24,000 30,000 36,000 42,000 192,000
Cost per Unit * $ 6.00 $ 6.00 $ 6.00 $ 6.00 $ 6.00 $ 6.00
* Note: Cost per Unit as indicated above represents Licensee's Cost
32
EXHIBIT E PAGE 2 OF 2
SALES PROJECTIONS
Year 2 >>
-------------
Month >>> 13 14 15 16 17 18
-------------------------------------------------------------------------------------
--------------
DEVICES
--------------
Qualitative
--------------
HIV 1 and 2
Total No. of Units 70,000 85,000 100,000 130,000 160,000 190,000
Bulk 80% No. of Units 56,000 68,000 80,000 104,000 128,000 152,000
Cost per Unit * $ 6.50 $ 6.50 $ 6.50 $ 6.50 $ 6.50 $ 6.50
Individually Pack20%d No. of Units 14,000 17,000 20,000 26,000 32,000 38,000
Cost per Unit * $ 7.50 $ 7.50 $ 7.50 $ 7.50 $ 7.50 $ 7.50
Six Additional Devices No of Units 14,000 17,000 20,000 26,000 32,000 38,000
Rubella Cost per Unit * $ 7.50 $ 7.50 $ 7.50 $ 7.50 $ 7.50 $ 7.50
CMV (Herpes)
Rotavirus
Streptococci Group A
HCG (Pregnancy)
Infectious Mononucleosis
Quantitative
--------------
Cardiac System
Myoglobin No. of Units 70,000 85,000 100,000 130,000 160,000 190,000
CK - MB No. of Units 140,000 170,000 200,000 260,000 320,000 380,000
Cardiac Troponin - 1 No. of Units 140,000 170,000 200,000 260,000 320,000 380,000
Cost per Unit * $ 5.00 $ 5.00 $ 5.00 $ 5.00 $ 5.00 $ 5.00
Initial CRP Device and two No. of Units 70,000 85,000 100,000 130,000 160,000 190,000
additional new tests per Cost per Unit * $ 8.50 $ 8.50 $ 8.50 $ 8.50 $ 8.50 $ 8.50
quarter
Multiple Mobile Assay Analyzer No. of Units 2,100 2,550 3,000 3,900 4,800 5,700
--------------------------------------
Cost per Unit * 300 $ 300 $ 300 $ 300 $ 300 $ 300
--------------
DRUG TESTS
--------------
Drug Cup
Total No. of Units 250,000 290,000 330,000 390,000 450,000 510,000
Bulk 80% No. of Units 200,000 232,000 264,000 312,000 360,000 408,000
Cost per Unit * $ 5.00 $ 5.00 $ 5.00 $ 5.00 $ 5.00 $ 5.00
Individually Pa20%ged No. of Units 50,000 58,000 66,000 78,000 90,000 102,000
Cost per Unit * $ 6.00 $ 6.00 $ 6.00 $ 6.00 $ 6.00 $ 6.00
Total
19 20 21 22 23 24 Year 2
-------------------------------------------------------------------------------------
--------------
DEVICES
--------------
Qualitative
--------------
HIV 1 and 2
Total 235,000 280,000 325,000 380,000 440,000 500,000 2,895,000
Bulk 80% 188,000 224,000 260,000 304,000 352,000 400,000 2,316,000
$ 6.50 $ 6.50 $ 6.50 $ 6.50 $ 6.50 $ 6.50
Individually Pack20%d 47,000 56,000 65,000 76,000 88,000 100,000 579,000
$ 7.50 $ 7.50 $ 7.50 $ 7.50 $ 7.50 $ 7.50
Six Additional Devices 47,000 56,000 65,000 76,000 88,000 100,000 579,000
Rubella $ 7.50 $ 7.50 $ 7.50 $ 7.50 $ 7.50 $ 7.50
CMV (Herpes)
Rotavirus
Streptococci Group A
HCG (Pregnancy)
Infectious Mononucleosis
Quantitative
--------------
Cardiac System
Myoglobin 235,000 280,000 325,000 380,000 440,000 500,000 2,895,000
CK - MB 470,000 560,000 650,000 760,000 880,000 1,000,000 5,790,000
Cardiac Troponin - 1 470,000 560,000 650,000 760,000 880,000 1,000,000 5,790,000
$ 5.00 $ 5.00 $ 5.00 $ 5.00 $ 5.00 $ 5.00
Initial CRP Device and two 235,000 280,000 325,000 380,000 440,000 500,000 2,895,000
additional new tests per $ 8.50 $ 8.50 $ 8.50 $ 8.50 $ 8.50 $ 8.50
quarter
Multiple Mobile Assay Analyzer 7,050 8,400 9,750 11,400 13,200 15,000 86,850
--------------------------------------
$ 300 $ 300 $ 300 $ 300 $ 300 $ 300
--------------
DRUG TESTS
--------------
Drug Cup
Total 580,000 650,000 720,000 810,000 900,000 1,000,000 6,880,000
Bulk 80% 464,000 520,000 576,000 648,000 720,000 800,000 5,504,000
$ 5.00 $ 5.00 $ 5.00 $ 5.00 $ 5.00 $ 5.00
Individually Pa20%ged 116,000 130,000 144,000 162,000 180,000 200,000 1,376,000
$ 6.00 $ 6.00 $ 6.00 $ 6.00 $ 6.00 $ 6.00
* Note: Cost per Unit as indicated above represents Licensee's Cost
33
